BTBP has continuously received a Wind ESG A rating, with a comprehensive score of 7.02同壁财经·Jun 2 at 09:10 PM6001610.00%
BTBP: Reviewed the third quarterly report, adjusted the structure, and acquired 1% equity in Songzi Pulp StationZhitong·Oct 24, 2025 at 04:29 AM6001610.00%
BTBP: Recently officially launched Phase III clinical trials for human prothrombin complexZhitong·Oct 21, 2025 at 04:34 AM6001610.00%
BTBP: Tiantan Kunming has been approved to conduct clinical trials for "human fibrinogen"Zhitong·Sep 30, 2025 at 04:23 AM6001610.00%
BTBP's subsidiary received a notice of compliance inspection for drug GMPZhitong·Sep 22, 2025 at 05:17 AM6001610.00%
Beijing BTBP 2025 Half-Year Equity Distribution Implementation Announcement ReleasedZhitong·Sep 18, 2025 at 02:57 AM6001610.00%
BTBP released its performance for the first half of the year, with a net profit attributable to the parent company of 633 million yuan, a year-on-year decrease of 12.88%Zhitong·Aug 21, 2025 at 07:36 AM6001610.00%
BTBP's net profit attributable to the parent company in the first half of the year was 633 million yuan, a year-on-year decrease of 12.88%Zhitong·Aug 6, 2025 at 04:18 AM6001610.00%
BTBP plans to abandon the acquisition of PLBIO business opportunityZhitong·Aug 4, 2025 at 04:18 AM000403+0.10%6001610.00%
The biopharmaceutical sector saw a short-term surge, with BTBP hitting the daily limitZhitong·Aug 4, 2025 at 12:59 AM000403+0.10%6001610.00%
CITIC Securities: Maintain "Buy" rating on BTBP, new production capacity is expected to improve production efficiencyZhitong·Jul 22, 2025 at 02:57 AM6001610.00%
BTBP: Intravenous immunoglobulin has received approval for a supplemental drug applicationZhitong·Jul 8, 2025 at 04:18 AM6001610.00%
BTBP: The production workshop of Chengdu Rongsheng Blood Products, a subsidiary, meets national GMP requirementsZhitong·Jun 24, 2025 at 08:34 AM6001610.00%
298 stocks received buy ratings from brokerages, AUTEK's target price increase reaches 68.48%Zhitong·Apr 27, 2025 at 07:33 PM300595+0.97%002463+7.46%
